1. ALLA AKTIER
  2. NYHETER
  3. ORTIVUS

Ortivus

Nyheter Ortivus Nyheter alla bolag

Ortivus AB (publ) interim report for the period July – September 2022

MAR

Ortivus continues to gain market share and component shortages affect deliveries

Highlights July - September 2022

  • Ortivus received an order for updated hardware to the ambulance service in Northern Ireland, which has been the company’s customer since 2019. The order value is estimated to 3.2 MSEK.
  • Region Blekinge awards Ortivus a contract on new equipment for the region’s ambulance operations to a value of 4.5 MSEK.
  • Region Gävleborg’s ambulance and hospital services awards Ortivus a contract regarding the delivery of Ortivus’ solution MobiMed Life and the order value is estimated to 4.0 MSEK.

Significant events after end of the period

  • Ortivus entered into a strategic distribution agreement with the Spanish company ITURRI, a well-established supplier to several sectors such as healthcare and the defense industry.
  • Ortivus communicates the start-up of a Danish subsidiary, Ortivus MobiMed ApS.


July - September 2022

  • Net sales amounted to 20.2 (24.5) MSEK.
  • The gross margin amounted to 44% (51%).
  • Profit after tax amounted to 0.2 (2.7) MSEK.
  • Earnings after tax per share before and after dilution amounted to 0.01 (0.06) SEK.
  • Operating cash flow before changes in working capital amounted to -8.0 (12.2) MSEK.

January - September 2022

  • Net sales amounted to 71.2 (71.7) MSEK.
  • The gross margin amounted to 50% (50%).
  • Profit after tax amounted to 5.7 (7.6) MSEK.
  • Earnings after tax per share before and after dilution amounted to 0.13 (0.17) SEK.
  • Operating cash flow before changes in working capital amounted to -8.8 (13.8) MSEK.

Jul-Sep 2022Jul-Sep 2021Jan-Sep 2022Jan-Sep 2021Jan-Dec 2021
Net sales (MSEK)20.224.571.271.794.3
Gross margin (%)44%51%50%50%51%
Operating profit (MSEK)0.02.75.57.69.3
Operating margin (%)0%11%8%11%10%
EBITDA (MSEK)2.13.19.18.212.7

Contacts

For further information, please contact

Reidar Gårdebäck, CEO

Telefon +46 8 446 45 00

About Ortivus

Ortivus develops and commercialises MobiMed, medical technology solutions for a safer and more efficient
healthcare. The company was founded in 1985 and is today a leading provider of mobile digital
solutions for prehospital care, worldwide. Ortivus' products are based on in-depth expertise
in cardiology as well as decades of development together with users and customers. The company's headquarters are located in Danderyd, Stockholm and the company has, since 1998, a wholly-owned subsidiary based in the United Kingdom.

MobiMed is a modular platform that currently is used by over 12,000 paramedics in over 2,700 emergency vechicles. The platform consists of a monitor that in real-time measures, monitors and shares patients'
vital parameters, such as, ECG, blood pressure and blood oxygenation. The system also consists
of an electronic patient record for decision support, collection of patient data and clinical documentation.
MobiMed has a total weight of 3.5kg and is created to function in a demanding environment and out in
the field. The two-way communication supports telemedicine consulting with clinical experts while patient data is seamlessly integrated into the medical records at the hospitals and primary care centers. MobiMed saves time and helps healthcare professionals make the right decisions in critical situations. MobiMed also contributes to improved quality of care and saved resources.

Ortivus Class A and Class B shares are listed on the NASDAQ Stockholm Small Cap list.

Read more about Ortivus at www.ortivus.com

This information is information that Ortivus is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2022-11-11 08:30 CET.

Attachments

Interim Report For Ortivus Jul Sep 2022

Datum 2022-11-11, kl 08:30
Källa MFN
Bifogade filer
Interim Report For Ortivus Jul Sep 2022
Affiliate
SAVR är investeringsplattformen som utmanar branschen och gör det både enklare och roligare att investera. Betala aldrig för mycket! Alla aktier och ETF:er från 1 kr, och få upp till 50 % rabatt på alla fonder. Automatiskt courtage och samma enkla prismodell på alla marknader.
Investeringar i värdepapper och fonder innebär alltid en risk och det är inte säkert att du får tillbaka det investerade kapitalet